Printer Friendly Version
Printer Friendly Version
L.5.01.523
Nuedexta (dextromethorphan hydrobromide and quinidine sulfate)
Please perform a formulary drug search on your patient’s member ID to ensure the prescription drug is covered under their benefit plan. The medication(s) in this medical policy may not be covered under a specific member’s benefit plan.
Pseudobulbar affect (PBA) is a condition characterized by episodes of sudden, involuntary, and frequent episodes of crying and/or laughing. PBA involves a deficit in regulation of emotional expression and occurs secondary to a variety of otherwise unrelated neurological conditions, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s disease (AD), stroke, traumatic brain jury, and parkinsonian disorders.
Nuedexta is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) and is indicated for the treatment of PBA.
Quantity Limits
Drug Name/Strength | Quantity Limit |
Nuedexta 20-10mg | 60 caps per month |
Prior authorization is required.
The use of samples by an individual will not be considered current or stable therapy to satisfy Medical Policy requirements.
Initial Evaluation
Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) may be considered medically necessary when ALL of the following criteria are met:
The individual is >18 years old;
The individual has a documented diagnosis of pseudobulbar affect;
The individual does not have any FDA labeled contraindications to therapy with the requested agent; AND
The prescribed dosage is within the FDA approved labeled dose range.
Length of Approval: 12 months
Renewal Evaluation
Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) may be approved for RENEWAL when ALL of the following criteria are met:
The individual has been previously approved for treatment through the BCBSMS PA process;
The individual has documented clinical improvement (i.e., decrease in symptom severity and/or frequency);
The individual does not have any FDA labeled contraindications to therapy with the requested agent; AND
The prescribed dosage is within the FDA approved labeled dose range.
Length of Approval: 12 months
State Health Plan (State and School Employees): The prescription drug(s) in this medical policy may be covered under a prescription drug benefit plan administered by the State Health Plan’s Pharmacy Benefit Manager. Please perform a formulary drug search at https://www.dfa.ms.gov/cvs-caremark and submit any required Prior Authorization Requests for coverage determination to the Plan’s Pharmacy Benefit Manager. Services related to delivery and/or administration of a medication determined to be not medically necessary will also be considered not medically necessary. Services related to delivery and/or administration of a self-administered drug are not covered.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Mental Health Disorders, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:
A. consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and
B. appropriate with regard to standards of good medical practice; and
C. not solely for the convenience of the Member, his or her Provider; and
D. the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.
For the definition of medical necessity, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary. BCBSMS may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
BCBSMS determines patient medication trial and adherence by a review of pharmacy claims data over the preceding twelve months. Additional information may be requested on a case-by-case basis to allow for proper review. If member is new to BCBSMS and pharmacy records are needed to confirm medication trials and adherence, it is the responsibility of the member and/or requesting provider to obtain said records and to submit them to BCBSMS upon request. Medical records from the provider that list previously prescribed medications will not be sufficient to show medication trials or adherence.
04/01/2019: New policy added. Policy reviewed and approved by Pharmacy & Therapeutics (P&T) Committee.
11/01/2020: Policy reviewed and approved by Pharmacy & Therapeutics (P&T) Committee. Policy description updated to add quantity limits. Policy section updated to list medically necessary criteria. Added renewal evaluation criteria. Policy Guidelines updated to change "Nervous/Mental Conditions" to "Mental Health Disorders" and to add information regarding BCBSMS request for medical records. Sources updated.
02/01/2023: Policy Exceptions updated to add the following: State Health Plan (State and School Employees): The prescription drug(s) in this medical policy may be covered under a prescription drug benefit plan administered by the State Health Plan’s Pharmacy Benefit Manager. Please perform a formulary drug search at https://www.dfa.ms.gov/cvs-caremark and submit any required Prior Authorization Requests for coverage determination to the Plan’s Pharmacy Benefit Manager. Services related to delivery and/or administration of a medication determined to be not medically necessary will also be considered not medically necessary. Services related to delivery and/or administration of a self-administered drug are not covered.
12/16/2024: Policy reviewed and approved by Pharmacy & Therapeutics (P&T) Committee. Policy description updated to add indication for Nuedexta (dextromethorphan hydrobromide and quinidine sulfate). Policy statement updated to state that the use of samples by a Member will not be considered current or stable therapy to satisfy Medical Policy requirements. Policy statement criteria updated to change "patient" to "individual." Sources updated.
12/02/2025: Policy reviewed and approved by the Pharmacy & Therapeutics (P&T) Committee. Policy description updated regarding pseudobulbar affect and Nuedexta. Policy statement updated to change "Member" to "individual." Sources updated.
Hakimi M, Maurer CW. Pseudobulbar Affect in Parkinsonian Disorders: A Review. J Mov Disord. 2019;12(1):14-21.
Nuedexta prescribing information. Otsuka America Pharmaceutical, Inc. November 2024. Last accessed September 2025.
None